WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada's biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and Canada and reinforce Canada's commitment to long-term readiness and advanced strategic stockpiling. Emergent will receive more than $35M million CAD in orders in 2026.

Under these agreements, Emergent will supply four medical countermeasures to protect against or treat biological threats. Committed annual procurements from Canadian authorities will help ensure continuous production and reliable supply of these critical countermeasures, as well as surge manufacturing capacity if required. Several of the medical countermeasures supplied under these agreements are manufactured at Emergent's Health Canada–licensed facility in Canada, reinforcing domestic production capacity for critical health security assets, supporting highly skilled biomanufacturing jobs, and strengthening Canada's ...